These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 33096480)

  • 1. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
    Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
    EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
    Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
    Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
    Singh RR; Kunkalla K; Qu C; Schlette E; Neelapu SS; Samaniego F; Vega F
    Oncogene; 2011 Dec; 30(49):4874-86. PubMed ID: 21625222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.
    Ciavarella S; Vegliante MC; Fabbri M; De Summa S; Melle F; Motta G; De Iuliis V; Opinto G; Enjuanes A; Rega S; Gulino A; Agostinelli C; Scattone A; Tommasi S; Mangia A; Mele F; Simone G; Zito AF; Ingravallo G; Vitolo U; Chiappella A; Tarella C; Gianni AM; Rambaldi A; Zinzani PL; Casadei B; Derenzini E; Loseto G; Pileri A; Tabanelli V; Fiori S; Rivas-Delgado A; López-Guillermo A; Venesio T; Sapino A; Campo E; Tripodo C; Guarini A; Pileri SA
    Ann Oncol; 2018 Dec; 29(12):2363-2370. PubMed ID: 30307529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
    Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
    Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.
    Carreras J; Yukie Kikuti Y; Miyaoka M; Hiraiwa S; Tomita S; Ikoma H; Kondo Y; Shiraiwa S; Ando K; Sato S; Suzuki Y; Miura I; Roncador G; Nakamura N
    Am J Surg Pathol; 2018 Jul; 42(7):936-950. PubMed ID: 29738359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
    Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
    Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma.
    Liu M; Bertolazzi G; Sridhar S; Lee RX; Jaynes P; Mulder K; Syn N; Hoppe MM; Fan S; Peng Y; Thng J; Chua R; Jayalakshmi ; Batumalai Y; De Mel S; Poon L; Chan EHL; Lee J; Hue SS; Chang ST; Chuang SS; Chandy KG; Ye X; Pan-Hammarström Q; Ginhoux F; Chee YL; Ng SB; Tripodo C; Jeyasekharan AD
    Nat Commun; 2024 Mar; 15(1):2113. PubMed ID: 38459052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.
    Cioroianu AI; Stinga PI; Sticlaru L; Cioplea MD; Nichita L; Popp C; Staniceanu F
    Anal Cell Pathol (Amst); 2019; 2019():8586354. PubMed ID: 31934533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Potential of Enhanced Prognostic Performance of NCCN-IPI in Diffuse Large B-Cell Lymphoma by Integrating Tumor Microenvironment Markers: Stromal FOXC1 and Tumor pERK1/2 Expression.
    Kim JY; Kahttana I; Yoon H; Chang S; Yoon SO
    Cancer Med; 2024 Oct; 13(19):e70305. PubMed ID: 39404228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles.
    Dubois S; Tesson B; Mareschal S; Viailly PJ; Bohers E; Ruminy P; Etancelin P; Peyrouze P; Copie-Bergman C; Fabiani B; Petrella T; Jais JP; Haioun C; Salles G; Molina TJ; Leroy K; Tilly H; Jardin F;
    EBioMedicine; 2019 Oct; 48():58-69. PubMed ID: 31648986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
    Lupino L; Perry T; Margielewska S; Hollows R; Ibrahim M; Care M; Allegood J; Tooze R; Sabbadini R; Reynolds G; Bicknell R; Rudzki Z; Lin Hock Y; Zanetto U; Wei W; Simmons W; Spiegel S; Woodman CBJ; Rowe M; Vrzalikova K; Murray PG
    Leukemia; 2019 Dec; 33(12):2884-2897. PubMed ID: 31097785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.
    Alizadeh AA; Gentles AJ; Alencar AJ; Liu CL; Kohrt HE; Houot R; Goldstein MJ; Zhao S; Natkunam Y; Advani RH; Gascoyne RD; Briones J; Tibshirani RJ; Myklebust JH; Plevritis SK; Lossos IS; Levy R
    Blood; 2011 Aug; 118(5):1350-8. PubMed ID: 21670469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 19. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
    Wright GW; Huang DW; Phelan JD; Coulibaly ZA; Roulland S; Young RM; Wang JQ; Schmitz R; Morin RD; Tang J; Jiang A; Bagaev A; Plotnikova O; Kotlov N; Johnson CA; Wilson WH; Scott DW; Staudt LM
    Cancer Cell; 2020 Apr; 37(4):551-568.e14. PubMed ID: 32289277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.